Highlight
– Intensive LDL cholesterol lowering with evolocumab in T1DM patients with ASCVD shows a trend toward substantial reduction in major cardiovascular events.
– The FOURIER trial revealed a 7.3% absolute risk reduction for the primary composite endpoint in T1DM, surpassing reductions seen in T2DM and non-diabetic groups.
– Despite small T1DM sample size limiting statistical power, findings underscore unmet need for targeted lipid-lowering strategies in this population.
– Further large randomized trials specifically in T1DM individuals with ASCVD are warranted to confirm these clinical benefits.
Study Background and Disease Burden
Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality in individuals with diabetes mellitus. While type 2 diabetes mellitus (T2DM) is commonly associated with a wide array of cardiovascular complications, type 1 diabetes mellitus (T1DM) patients also carry a considerable risk due to longstanding hyperglycemia and metabolic abnormalities. Despite optimized glycemic control and statin therapy, T1DM patients continue to experience elevated rates of atherosclerotic cardiovascular disease (ASCVD), highlighting a critical unmet medical need for further cardiovascular risk reduction strategies. Low-density lipoprotein cholesterol (LDL-C) is a well-established modifiable risk factor for ASCVD. The PCSK9 inhibitor evolocumab significantly lowers LDL-C and reduces cardiovascular events in broad populations with ASCVD, predominantly studied in T2DM and non-diabetic cohorts. However, data specific to T1DM patients are scarce, limiting evidence-based guidance for lipid management in this subgroup. This study evaluates the efficacy of evolocumab added to statins in T1DM patients enrolled in the FOURIER trial to provide insights into cardiovascular outcomes and guide clinical decision-making.
Study Design
The Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) trial was a randomized, double-blind, placebo-controlled study enrolling 27,564 participants with established ASCVD already receiving statin therapy. Participants were randomized to receive either evolocumab or placebo, with a median follow-up of 2.2 years. The primary endpoint was a composite of cardiovascular death, myocardial infarction (MI), stroke, hospitalization for unstable angina, or coronary revascularization. Of the full cohort, 10,834 individuals had T2DM, 197 had T1DM, and the remainder had no diabetes. The trial compared event rates and hazard ratios between evolocumab and placebo arms stratified by diabetes status.
Key Findings
Over 2.5 years, the Kaplan-Meier rates for the primary endpoint demonstrated a gradient of increasing cardiovascular risk across groups: 11.0% for participants without diabetes, 15.2% in T2DM, and 20.4% in T1DM receiving placebo (P < 0.0001). The hazard ratios (HR) for the primary endpoint with evolocumab versus placebo were 0.87 (95% CI 0.79-0.96) in the no diabetes group, 0.84 (0.75-0.93) for T2DM, and 0.66 (0.32-1.38) in T1DM. Although the confidence interval for T1DM included 1.0, indicative of statistical uncertainty due to the small sample size, the point estimate suggests a 34% relative risk reduction. Absolute risk reduction (ARR) was markedly higher in T1DM at 7.3%, compared to 2.5% in T2DM and 1.3% in non-diabetes participants, reflecting the higher baseline event rate in T1DM and potential for greater benefit.
Safety outcomes showed evolocumab was well tolerated without significant increases in adverse events across all groups, consistent with the known safety profile of PCSK9 inhibitors.
Expert Commentary
The FOURIER trial uniquely provides early evidence supporting intensive LDL-C lowering with evolocumab in T1DM patients with established ASCVD, a population traditionally underrepresented in cardiovascular outcome trials. The higher baseline risk and substantial absolute risk reduction observed imply that aggressive lipid lowering could translate to meaningful clinical benefits in T1DM. However, the limited sample size of T1DM participants necessitates cautious interpretation and highlights the need for further dedicated randomized controlled trials to validate these findings. Biological plausibility is strong, as PCSK9 inhibition effectively reduces LDL-C, a key driver of atherosclerosis, which contributes to cardiovascular risk regardless of diabetes type. Clinicians should consider comprehensive cardiovascular risk assessment and individualized lipid management strategies, including PCSK9 inhibitors, for high-risk T1DM patients.
Conclusion
The FOURIER trial illuminates the potential of evolocumab to markedly lower cardiovascular event risk in individuals with T1DM and established ASCVD. While definitive confirmation awaits larger and longer-term studies, these findings advocate for intensified LDL-C lowering as a valuable therapeutic approach in this vulnerable population. This study underscores the pressing need for clinical trials specifically designed to evaluate cardiovascular outcomes in T1DM, ultimately to inform guidelines and optimize patient care.
References
1. Kang YM, Giugliano RP, Ran X, Deedwania P, De Ferrari GM, George JT, et al. Cardiovascular Outcomes and Efficacy of the PCSK9 Inhibitor Evolocumab in Individuals With Type 1 Diabetes: Insights From the FOURIER Trial. Diabetes Care. 2025 Sep 1;48(9):1512-1516. doi: 10.2337/dc25-0942. PMID: 40544474; PMCID: PMC12368373.
2. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713-1722.
3. American Diabetes Association. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2024. Diabetes Care. 2024 Jan;47(Suppl 1):S134-S145.